Ash A. Alizadeh

75.6k citations

251 papers · 35.5k indexed · 19 hit papers · h-index 66

Molecular Biology top 0.1%
Oncology top 0.05%
Immunology top 0.05%
Cancer Research top 0.02%
Pulmonary and Respiratory Medicine top 0.05%

Co-authors: Chih Long Liu Aaron M. Newman Maximilian Diehn Andrew J. Gentles Weiguo Feng Chuong D. Hoang Yue Xu Michael R. Green
Topics: Cancer Genomics and Diagnostics (86 papers)Lymphoma Diagnosis and Treatment (76 papers)CAR-T cell therapy research (29 papers)
Cited by: Cancer Research Immunology Oncology
Journals: New England Journal of Medicine Cell Proceedings of the National Academy of Sciences
Partner nations: United States Iran Germany

In The Last Decade

Ash A. Alizadeh

232 papers receiving 35.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Robust enumeration of cell subsets from tissue expression profiles

2015 8.3k citations Aaron M. Newman, Chih Long Liu et al. profile →
Profiling Tumor Infiltrating Immune Cells with CIBERSORT

2018 2.4k citations Binbin Chen, Michael S. Khodadoust et al. profile →
Determining cell type abundance and expression from bulk tissues with digital cytometry

2019 2.4k citations Aaron M. Newman, Chih Long Liu et al. Nature Biotechnology profile →
The prognostic landscape of genes and infiltrating immune cells across human cancers

2015 2.2k citations Andrew J. Gentles, Aaron M. Newman et al. profile →
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

2014 1.5k citations Aaron M. Newman, Scott V. Bratman et al. profile →
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

2009 1.3k citations Ravindra Majeti, Mark P. Chao et al. Cell profile →
Genome-wide analysis of DNA copy-number changes using cDNA microarrays

1999 1.1k citations Ash A. Alizadeh et al. profile →
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

2010 845 citations Mark P. Chao, Ash A. Alizadeh et al. Cell profile →
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

2001 815 citations Ash A. Alizadeh, Wyndham H. Wilson et al. profile →
Integrated digital error suppression for improved detection of circulating tumor DNA

2016 716 citations Aaron M. Newman, Alexander F. Lovejoy et al. Nature Biotechnology profile →
Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds

2004 711 citations Ash A. Alizadeh, Robert B. West et al. profile →
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

2004 708 citations Debra K. Czerwinski, Ash A. Alizadeh et al. profile →
Individuality and variation in gene expression patterns in human blood

2003 618 citations Maximilian Diehn, Ash A. Alizadeh et al. profile →
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

2010 594 citations Mark P. Chao, Rachel Weissman-Tsukamoto et al. profile →
Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays

1999 531 citations Ash A. Alizadeh, Matt van de Rijn et al. profile →
From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment

2023 282 citations Kyle Swanson, Eric Q. Wu et al. Cell profile →
Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx

2020 275 citations Chih Long Liu, Ash A. Alizadeh et al. profile →
Postbiotics produced by lactic acid bacteria: The next frontier in food safety

2020 247 citations Ash A. Alizadeh et al. profile →
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

2024 93 citations Takeshi Sugio, Chih Long Liu et al. profile →

Peers

Countries citing papers authored by Ash A. Alizadeh

Since Specialization

Citations

This map shows the geographic impact of Ash A. Alizadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ash A. Alizadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ash A. Alizadeh more than expected).

Fields of papers citing papers by Ash A. Alizadeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ash A. Alizadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ash A. Alizadeh. The network helps show where Ash A. Alizadeh may publish in the future.

Co-authorship network of co-authors of Ash A. Alizadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Ash A. Alizadeh. A scholar is included among the top collaborators of Ash A. Alizadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ash A. Alizadeh. Ash A. Alizadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nanotechnology for effective bovine mastitis treatment: Applications in biosensors and vaccines 2025 ·OpenNano ·Soheil Sadr,Babak Khoramian,(unknown),Ash A. Alizadeh,Abbas Rahdar,Hassan Borji	1
2	Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial 2025 ·Nature Communications ·Paolo Strati,Lei Feng,Jason R. Westin,Ranjit Nair,Luis Fayad,Maria Alma Rodriguez,Dai Chihara,Luis Malpica,Jared Henderson,(unknown),(unknown),Iris Wang,(unknown),(unknown),David M. Kurtz,Stefan Alig,Christopher R. Flowers,Ash A. Alizadeh,Sattva S. Neelapu	0
3	Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma 2025 ·Journal of Clinical Oncology ·Mark Roschewski,David M. Kurtz,Jason R. Westin,Ryan C. Lynch,Ajay K. Gopal,Stefan Alig,Brian J. Sworder,(unknown),Christian Kuffer,Derek Blair,Krystal Brown,Jordan Goldstein,André Schultz,Sandra Close,Jacob J. Chabon,Maximilian Diehn,Wyndham H. Wilson,Ash A. Alizadeh	0
4	Online diabetes self-management education application for reducing glycated hemoglobin level among patients with type 1 diabetes mellitus: a systematic review and meta-analysis 2024 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Ash A. Alizadeh,Mehrdad Savabi Far	0
5	MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS 2023 ·Hematological Oncology ·Mark Roschewski,David M. Kurtz,Jason R. Westin,Ryan C. Lynch,Stefan Alig,Calum MacAulay,Christian Kuffer,(unknown),André Schultz,Sandra Close,(unknown),Davide Rossi,Stephen Opat,Rodney J. Hicks,Mark Hertzberg,Maximilian Diehn,Wyndham H. Wilson,Ash A. Alizadeh	5
6	From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatmentbreakdown → 2023 ·Cell ·Kyle Swanson,Eric Q. Wu,Angela Zhang,Ash A. Alizadeh,James Zou	282
7	Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma 2023 ·Blood ·Joseph G. Schroers‐Martin,Jurik Mutter,Mohammad Shahrokh Esfahani,Florian Scherer,Joanne Soo,Stefan Alig,David M. Kurtz,Takeshi Sugio,(unknown),Benoît Tessoulin,Mari Olsen,Chih Long Liu,Maximilian Diehn,Ash A. Alizadeh	0
8	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity 2022 ·Blood Cancer Discovery ·Tanaya Shree,Vishnu Shankar,(unknown),Debra K. Czerwinski,Joseph G. Schroers‐Martin,(unknown),Sara Beygi,(unknown),(unknown),(unknown),David M. Kurtz,Michael S. Khodadoust,Neel K. Gupta,Lauren S. Maeda,Ranjana H. Advani,Ash A. Alizadeh,Ronald Levy	27
9	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma 2020 ·Clinical Cancer Research ·William P. Accomando,(unknown),Daniel J. Hogan,Aaron M. Newman,(unknown),Ash A. Alizadeh,Maximilian Diehn,Oscar R. Diago,Dawn Gammon,Ali Haghighi,Harry E. Gruber,Douglas J. Jolly,Derek Ostertag	17
10	Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation 2019 ·Blood ·(unknown),Binbin Chen,Michael S. Khodadoust,Niclas Olsson,Mark M. Davis,Joshua E. Elias,Ronald Levy,Russ B. Altman,Ash A. Alizadeh	4
11	Predicting HLA class II antigen presentation through integrated deep learning 2019 ·Nature Biotechnology ·Binbin Chen,Michael S. Khodadoust,Niclas Olsson,Lisa E. Wagar,Ethan Fast,Chih Long Liu,Yagmur Muftuoglu,Brian J. Sworder,Maximilian Diehn,Ronald Levy,Mark M. Davis,Joshua E. Elias,Russ B. Altman,Ash A. Alizadeh	209
12	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA 2018 ·Cancer Discovery ·Jonathan C. Dudley,Joseph G. Schroers‐Martin,Daniel Lazzareschi,William Y. Shi,Simon Chen,Mohammad Shahrokh Esfahani,Dharati R. Trivedi,Jacob J. Chabon,Aadel A. Chaudhuri,Henning Stehr,Chih Long Liu,(unknown),Helio A. Costa,Barzin Y. Nabet,Mandy L.Y. Sin,Joseph C. Liao,Ash A. Alizadeh,Maximilian Diehn	151
13	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma 2018 ·Clinical Cancer Research ·Joanna Przybył,Jacob J. Chabon,Lien Spans,Kristen N. Ganjoo,Sujay Vennam,Aaron M. Newman,Erna Forgó,Sushama Varma,Shirley Zhu,Maria Dêbiec‐Rychter,Ash A. Alizadeh,Maximilian Diehn,Matt van de Rijn	44
14	Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis 2017 ·Blood ·Joseph G. Schroers‐Martin,Florian Scherer,Joanne Soo,David M. Kurtz,Chih Long Liu,Henning Stehr,(unknown),Yasodha Natkunam,Maximilian Diehn,Bertrand Nadel,Sandrine Roulland,Ash A. Alizadeh	1
15	Role of KEAP1 / NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance 2016 ·Cancer Discovery ·Youngtae Jeong,Ngoc T. Hoang,Alexander F. Lovejoy,Henning Stehr,Aaron M. Newman,Andrew J. Gentles,William Kong,(unknown),Shanique Martin,Aadel A. Chaudhuri,Diane Heiser,Li Zhou,Carmen Say,Justin N. Carter,Susan M. Hiniker,Billy W. Loo,Robert B. West,Philip A. Beachy,Ash A. Alizadeh,Maximilian Diehn	243
16	CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer 2016 ·International Journal of Radiation OncologyBiologyPhysics ·Aadel A. Chaudhuri,Alex Lovejoy,Jacob J. Chabon,Aaron M. Newman,Henning Stehr,Carmen Say,Sonya Aggarwal,(unknown),Robert B. West,Joel W. Neal,Heather A. Wakelee,Billy W. Loo,Ash A. Alizadeh,Maximilian Diehn	3
17	Deoxynivalenol and Its Modified Forms: Are There Major Differences? 2016 ·Toxins ·Ash A. Alizadeh,Saskia Braber,Peyman Akbari,Aletta D. Kraneveld,Johan Garssen,Johanna Fink‐Gremmels	41
18	Utility Of Non-Invasive Monitoring Of Circulating Tumor DNA At Diagnosis, Interim Therapy, and Relapse Of DLBCL Using High-Throughput Sequencing Of Immunoglobulin Genes 2013 ·Blood ·Michael R. Green,Scott V. Bratman,Chih Long Liu,Kazuhiro Takahashi,Cynthia Glover,Colm Keane,Shingo Kihira,(unknown),Malek Faham,(unknown),David B. Miklos,Ranjana H. Advani,Ronald Levy,Mark Hertzberg,(unknown),Maher K. Gandhi,Maximilian Diehn,Ash A. Alizadeh	2
19	Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia 2010 ·Cancer Research ·Mark P. Chao,Ash A. Alizadeh,Chad Tang,Max Jan,Rachel Weissman-Tsukamoto,Feifei Zhao,Christopher Y. Park,Irving L. Weissman,Ravindra Majeti	294
20	The specific pattern of obsessive-compulsive symptoms in patients with bipolar disorder 2008 ·SHILAP Revista de lepidopterología ·Ash A. Alizadeh,Amir Shabani	10

About Ash A. Alizadeh

Ash A. Alizadeh is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology, having authored 251 papers that have together received 35.5k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (86 papers), Lymphoma Diagnosis and Treatment (76 papers) and CAR-T cell therapy research (29 papers). The work is most often cited by research in Cancer Research (9.5k citations), Immunology (10.6k citations) and Oncology (11.0k citations). Ash A. Alizadeh has collaborated with scholars based in United States, Iran and Germany. Frequent co-authors include Chih Long Liu, Aaron M. Newman, Maximilian Diehn, Andrew J. Gentles, Weiguo Feng, Chuong D. Hoang, Yue Xu, Michael R. Green, Michael S. Khodadoust and Patrick O. Brown. Their work appears in journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact